Summary
Thermo Fisher Scientific Inc. (TMO) reported its third-quarter and nine-month results for the period ending September 27, 2003. For the third quarter, revenues were $497.1 million, a 4% decrease year-over-year, primarily due to lower demand and divestitures, partially offset by favorable currency translation. Net income for the quarter was $48.5 million, a significant increase from $39.0 million in the prior year, largely driven by a gain on the disposal of discontinued operations. For the first nine months of 2003, revenues were $1.51 billion, a slight decrease from the prior year. Net income for the nine-month period was $138.1 million, down from $222.6 million in 2002, impacted by gains from discontinued operations in the prior year and increased restructuring costs in the current year. The company's balance sheet shows a decrease in cash and cash equivalents and short-term investments, reflecting strong cash usage in financing activities, including debt redemption and share repurchases. While revenues saw a slight decline in certain segments like Optical Technologies and Measurement and Control due to market downturns, the Life and Laboratory Sciences segment showed modest growth. The company is actively managing its cost structure through ongoing restructuring efforts, which are expected to be substantially completed by the end of 2004.
Key Highlights
- 1Revenues for the third quarter of 2003 decreased by 4% to $497.1 million compared to the prior year, impacted by lower demand and divestitures.
- 2Net income for the third quarter increased to $48.5 million from $39.0 million in the prior year, boosted by a significant gain on the disposal of discontinued operations.
- 3For the first nine months of 2003, revenues were $1.51 billion, a slight decrease from the previous year, while net income declined to $138.1 million from $222.6 million.
- 4The company utilized $697.8 million in cash for financing activities during the first nine months of 2003, including debt redemptions and share repurchases.
- 5Restructuring and other costs amounted to $14.3 million in Q3 2003, compared to $6.9 million in Q3 2002, reflecting ongoing cost-reduction initiatives.
- 6The Life and Laboratory Sciences segment showed resilience with a modest revenue increase in the third quarter, driven by favorable currency translation and growth in clinical diagnostic and laboratory informatics tools.
- 7Segments like Optical Technologies and Measurement and Control experienced revenue declines due to ongoing slowdowns in their respective end markets, particularly in semiconductor and industrial sectors.